Literature DB >> 33971010

Myeloid lncRNA LOUP mediates opposing regulatory effects of RUNX1 and RUNX1-ETO in t(8;21) AML.

Bon Q Trinh1, Simone Ummarino1, Yanzhou Zhang1, Alexander K Ebralidze1, Mahmoud A Bassal2,3, Tuan M Nguyen1,4, Gerwin Heller5, Rory Coffey1, Danielle E Tenen6, Emiel van der Kouwe7, Emiliano Fabiani8,9, Carmelo Gurnari8, Chan-Shuo Wu3, Vladimir Espinosa Angarica3, Henry Yang3, Sisi Chen1, Hong Zhang1, Abby R Thurm2,10, Francisco Marchi2,11, Elena Levantini1,2,12, Philipp B Staber7, Pu Zhang1, Maria Teresa Voso8, Pier Paolo Pandolfi13, Susumu S Kobayashi1,2,14, Li Chai2,15, Annalisa Di Ruscio1,16,17, Daniel G Tenen1,10.   

Abstract

The mechanism underlying cell type-specific gene induction conferred by ubiquitous transcription factors as well as disruptions caused by their chimeric derivatives in leukemia is not well understood. Here, we investigate whether RNAs coordinate with transcription factors to drive myeloid gene transcription. In an integrated genome-wide approach surveying for gene loci exhibiting concurrent RNA and DNA interactions with the broadly expressed Runt-related transcription factor 1 (RUNX1), we identified the long noncoding RNA (lncRNA) originating from the upstream regulatory element of PU.1 (LOUP). This myeloid-specific and polyadenylated lncRNA induces myeloid differentiation and inhibits cell growth, acting as a transcriptional inducer of the myeloid master regulator PU.1. Mechanistically, LOUP recruits RUNX1 to both the PU.1 enhancer and the promoter, leading to the formation of an active chromatin loop. In t(8;21) acute myeloid leukemia (AML), wherein RUNX1 is fused to ETO, the resulting oncogenic fusion protein, RUNX1-ETO, limits chromatin accessibility at the LOUP locus, causing inhibition of LOUP and PU.1 expression. These findings highlight the important role of the interplay between cell-type-specific RNAs and transcription factors, as well as their oncogenic derivatives in modulating lineage-gene activation and raise the possibility that RNA regulators of transcription factors represent alternative targets for therapeutic development.
© 2021 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33971010      PMCID: PMC8525335          DOI: 10.1182/blood.2020007920

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   25.476


  54 in total

1.  PU.1 expression is modulated by the balance of functional sense and antisense RNAs regulated by a shared cis-regulatory element.

Authors:  Alexander K Ebralidze; Florence C Guibal; Ulrich Steidl; Pu Zhang; Sanghoon Lee; Boris Bartholdy; Meritxell Alberich Jorda; Victoria Petkova; Frank Rosenbauer; Gang Huang; Tajhal Dayaram; Johanna Klupp; Karen B O'Brien; Britta Will; Maarten Hoogenkamp; Katherine L B Borden; Constanze Bonifer; Daniel G Tenen
Journal:  Genes Dev       Date:  2008-08-01       Impact factor: 11.361

2.  Predicting protein associations with long noncoding RNAs.

Authors:  Matteo Bellucci; Federico Agostini; Marianela Masin; Gian Gaetano Tartaglia
Journal:  Nat Methods       Date:  2011-06       Impact factor: 28.547

3.  The Runx-PU.1 pathway preserves normal and AML/ETO9a leukemic stem cells.

Authors:  Philipp B Staber; Pu Zhang; Min Ye; Robert S Welner; Elena Levantini; Annalisa Di Ruscio; Alexander K Ebralidze; Christian Bach; Hong Zhang; Junyan Zhang; Katrina Vanura; Ruud Delwel; Henry Yang; Gang Huang; Daniel G Tenen
Journal:  Blood       Date:  2014-09-03       Impact factor: 22.113

4.  Regulation of the PU.1 gene by distal elements.

Authors:  Y Li; Y Okuno; P Zhang; H S Radomska; H Chen; H Iwasaki; K Akashi; M J Klemsz; S R McKercher; R A Maki; D G Tenen
Journal:  Blood       Date:  2001-11-15       Impact factor: 22.113

5.  RUNX1 regulates the CD34 gene in haematopoietic stem cells by mediating interactions with a distal regulatory element.

Authors:  Elena Levantini; Sanghoon Lee; Hanna S Radomska; Christopher J Hetherington; Meritxell Alberich-Jorda; Giovanni Amabile; Pu Zhang; David A Gonzalez; Junyan Zhang; Daniela S Basseres; Nicola K Wilson; Steffen Koschmieder; Gang Huang; Dong-Er Zhang; Alexander K Ebralidze; Constanze Bonifer; Yutaka Okuno; Bertie Gottgens; Daniel G Tenen
Journal:  EMBO J       Date:  2011-08-26       Impact factor: 11.598

6.  Runx1 expression marks long-term repopulating hematopoietic stem cells in the midgestation mouse embryo.

Authors:  Trista E North; Marella F T R de Bruijn; Terryl Stacy; Laleh Talebian; Evan Lind; Catherine Robin; Michael Binder; Elaine Dzierzak; Nancy A Speck
Journal:  Immunity       Date:  2002-05       Impact factor: 31.745

7.  Densely interconnected transcriptional circuits control cell states in human hematopoiesis.

Authors:  Noa Novershtern; Aravind Subramanian; Lee N Lawton; Raymond H Mak; W Nicholas Haining; Marie E McConkey; Naomi Habib; Nir Yosef; Cindy Y Chang; Tal Shay; Garrett M Frampton; Adam C B Drake; Ilya Leskov; Bjorn Nilsson; Fred Preffer; David Dombkowski; John W Evans; Ted Liefeld; John S Smutko; Jianzhu Chen; Nir Friedman; Richard A Young; Todd R Golub; Aviv Regev; Benjamin L Ebert
Journal:  Cell       Date:  2011-01-21       Impact factor: 41.582

8.  PU.1 is a major downstream target of AML1 (RUNX1) in adult mouse hematopoiesis.

Authors:  Gang Huang; Pu Zhang; Hideyo Hirai; Shannon Elf; Xiaomei Yan; Zhao Chen; Steffen Koschmieder; Yutaka Okuno; Tajhal Dayaram; Joseph D Growney; Ramesh A Shivdasani; D Gary Gilliland; Nancy A Speck; Stephen D Nimer; Daniel G Tenen
Journal:  Nat Genet       Date:  2007-11-11       Impact factor: 38.330

9.  Identification of AML-1 and the (8;21) translocation protein (AML-1/ETO) as sequence-specific DNA-binding proteins: the runt homology domain is required for DNA binding and protein-protein interactions.

Authors:  S Meyers; J R Downing; S W Hiebert
Journal:  Mol Cell Biol       Date:  1993-10       Impact factor: 4.272

Review 10.  Disruption of differentiation in human cancer: AML shows the way.

Authors:  Daniel G Tenen
Journal:  Nat Rev Cancer       Date:  2003-02       Impact factor: 60.716

View more
  5 in total

Review 1.  Diverse functions of long noncoding RNAs in acute myeloid leukemia: emerging roles in pathophysiology, prognosis, and treatment resistance.

Authors:  Srishti Mishra; Jun Liu; Li Chai; Daniel G Tenen
Journal:  Curr Opin Hematol       Date:  2022-01-01       Impact factor: 3.284

2.  DesA Prognostic Risk Model of LncRNAs in Patients With Acute Myeloid Leukaemia Based on TCGA Data.

Authors:  Weidong Ding; Yun Ling; Yuan Shi; Zhuojun Zheng
Journal:  Front Bioeng Biotechnol       Date:  2022-02-21

3.  The effects of cannabidiol via TRPV2 channel in chronic myeloid leukemia cells and its combination with imatinib.

Authors:  Federica Maggi; Maria Beatrice Morelli; Daniele Tomassoni; Oliviero Marinelli; Cristina Aguzzi; Laura Zeppa; Massimo Nabissi; Giorgio Santoni; Consuelo Amantini
Journal:  Cancer Sci       Date:  2022-03-04       Impact factor: 6.716

4.  A direct comparison between AML1-ETO and ETO2-GLIS2 leukemia fusion proteins reveals context-dependent binding and regulation of target genes and opposite functions in cell differentiation.

Authors:  Yi-Fan Zhang; Xiao-Lin Wang; Chun-Hui Xu; Na Liu; Ling Zhang; Yu-Ming Zhang; Yin-Yin Xie; Yuan-Liang Zhang; Qiu-Hua Huang; Lan Wang; Zhu Chen; Sai-Juan Chen; Robert G Roeder; Shuhong Shen; Kai Xue; Xiao-Jian Sun
Journal:  Front Cell Dev Biol       Date:  2022-09-07

Review 5.  Alternative Splicing in Myeloid Malignancies.

Authors:  Carmelo Gurnari; Simona Pagliuca; Valeria Visconte
Journal:  Biomedicines       Date:  2021-12-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.